

# G rard DE POUVOURVILLE

Emeritus Professor

gdepouvourville@free.fr

Department: Economics

Campus de Cergy

## DIPLOMAS

---

### DIPLOMAS

- |      |  |
|------|--|
| 1978 | Doctorate in Economics and Business Administration<br>(Aix-Marseille Universit  France)    |
| 1974 | Dipl me d'Etudes Sup rieures in Economics<br>(Universit  Paris 1 Panth on-Sorbonne France) |
| 1970 | Graduate<br>( cole Polytechnique France)   |

## CAREER

---

### FULL-TIME ACADEMIC APPOINTMENTS

- |                   |   |
|-------------------|---|
| 2019 - Now        | Emeritus Professor (ESSEC Business School France) |
| 2007 - 2019-03-31 | Professor (ESSEC Business School France)          |

### OTHER APPOINTMENTS

- |                   |   |
|-------------------|---|
| 2006 - 2006-12-31 | Research teams manager, CERMES, INSERM U750, CNRS UMR 8169<br>(Institut national de la sant  et de la recherche m dicale (INSERM) France)   |
| 2003 - 2006-12-31 | Head of the Research Program « Epid miologie, Sant  Publique, Economie de la Sant  et Sciences Humaines et Sociales », at the Direction de la Recherche<br>(Gustave Roussy France)    |
| 2000 - 2005-12-31 | Head of the Centre de Recherche en Economie et Gestion Appliqu es   la Sant , INSERM U537, CNRS UMR 8052. (Institut national de la sant  et de la recherche m dicale (INSERM) France) |

- 1993 - 2000-12-31 Scientific Director of Groupe Information Médicale et Aide à la Gestion des Etablissements (IMAGE); by the CNRS. (École Nationale de la Santé Publique France)
- 1989 - 1993-12-31 Research Director, 2nd class, Centre de Recherche en Gestion (École Polytechnique France)
- 1989 - 1992-12-31 Research fellow, Groupe IMAGE (École Nationale de la Santé Publique France)
- 1981 - 1989-12-31 Research fellow, CNRS, Centre de Recherche en Gestion (École Polytechnique France)
- 1984 - 1984-12-31 Guest Researcher, Leonard Davis Institute for Health Economics (Université de Pennsylvanie United States of America)
- 1986 - 1986-12-31 Invited Researcher at Groupe de Recherche Interdisciplinaires en Santé (GRIS). Expert invited at the Commission d'Enquête sur les Services Sociaux et de Santé, Gouvernement du Québec. (Université de Montréal Canada)
- 1978 - 1981-12-31 Researcher, Centre de Recherche en Gestion (École Polytechnique France)
- 1973 - 1978-08-31 Doctorate, Centre de Recherche en Gestion (École Polytechnique France)
- 2000 - 2006-12-31 Head of the Etudes Médico-Economiques, part-time role (Gustave Roussy France)

## **OTHER ACADEMIC APPOINTMENTS**

- 2000 - 2006-12-31 Track Head, "Economie de la Santé", Master 2 Santé Publique. Teaching and Dissertation mentoring (Université Paris-Saclay France)
- 2000 - 2006-12-31 Supervisor of Economics and Management courses, Master Santé Publique, M1 (Université Paris-Saclay France)
- 2004 - 2006-12-31 Lecturer, Module « Préparation à la vie professionnelle », DCEM2, Faculté de Médecine de Bicêtre (Université Paris-Saclay France)
- 2000 - 2006-12-31 Lecturer, with Monique Kerleau, "Approche économique et théorie des organisations appliquées au système de soins", DESS Economie et Gestion des systèmes de santé (Université Paris 1 Panthéon-Sorbonne France)
- 1994 - 1999-12-31 Lecturer, Faculté de Médecine Saint-Louis-Lariboisière; teacher for the DEA "Système de soins hospitaliers et Société" (Director: Dominique Bertrand). Seminar "Evaluation des coûts à l'hôpital", seminar (with Alain Fontaine) "Préparation du mémoire de DEA". (Université Paris Cité France)

- 1986 - 1993-12-31 Lecturer; DEA 103 "Méthodes Scientifiques de Gestion" (Professor Bernard Roy) (Université Paris Dauphine-PSL France)
- 1998 - 2001-12-31 Associate Professor, Université de Lausanne (HEC Lausanne Switzerland)
- 1979 - 1980-12-31 Part-time lecturer, Institut Auguste Comte pour l'Etude des Sciences de l'Action. (École Polytechnique France)
- 1976 - 1977-12-31 Economics classes lecturer (École Nationale du Génie Rural et des Eaux et Forêts (ENGREF) France)
- 1973 - 1977-12-31 Economics class lecturer. In charge of the organization of final internships in Economics and Management. (École Polytechnique France)

## PUBLICATIONS

---

### BOOK CHAPTERS

[D'AUNNO, T., KIMBERLY, J. et PUYOU DE POUVOURVILLE, G. \(2008\). Conclusions: The Global Diffusion of Casemix. Dans: \*The Globalization of Managerial Innovation in Health Care\*. 1st ed. Cambridge University Press, pp. 346-372.](#)

[PUYOU DE POUVOURVILLE, G. \(2009\). L'économie de la santé : périmètre et questions de recherche. Dans: \*Traité d'économie et de gestion de la santé\*. 1st ed. Presses de Sciences Po, pp. 15-24.](#)

[PUYOU DE POUVOURVILLE, G. \(2007\). Les conséquences économiques des droits des malades. Dans: \*Les droits des malades et des usagers du système de santé, une législature plus tard\*. 1st ed. Presses de Sciences Po, pp. 53-58.](#)

[PUYOU DE POUVOURVILLE, G., BRAS, P.L. et TABUTEAU, D. \(2009\). L'industrie pharmaceutique en France. Dans: \*Traité d'économie et de gestion de la santé\*. 1st ed. Presses de Sciences Po, pp. 415-426.](#)

[PUYOU DE POUVOURVILLE, G. \(2009\). L'organisation des soins. Dans: \*Traité d'économie et de gestion de la santé\*. 1st ed. Presses de Sciences Po, pp. 401-406.](#)

[PUYOU DE POUVOURVILLE, G., CONTI, C. et BIBAULT, E. \(2009\). La distribution du médicament en France. Dans: \*Traité d'économie et de gestion de la santé\*. 1st ed. Presses de Sciences Po, pp. 427-434.](#)

[PUYOU DE POUVOURVILLE, G. \(2009\). Le financement des hôpitaux. Dans: \*Traité d'économie et de gestion de la santé\*. 1st ed. Presses de Sciences Po, pp. 269-274.](#)

[PUYOU DE POUVOURVILLE, G. \(2021\). La fabrication du prix du médicament. Dans: Thomas Barnay, Anne-Laure Sanson, Bruno Ventelou eds. \*Le système de santé français : aujourd'hui. Enjeux et défis\*. 1st ed. ESKA.](#)

[PUYOU DE POUVOURVILLE, G. \(2021\). Trente ans de dépenses de santé en France. Dans: René Demeleumeester, Jean-Calude Henrard, Bernadette Roussille, Patricia Siwek eds. \*Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?\* 1st ed. Boulogne-Billancourt: Berger-Levrault, pp. 255-270.](#)

[PUYOU DE POUVOURVILLE, G. \(2021\). Trente ans d'administration et de financement du système de soins. Dans: René Demeleumeester, Jean-Calude-Henrard, Bernadette Roussille, Patricia Siwek eds. \*Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?\* 1st ed. Boulogne-Billancourt: Berger-Levrault, pp. 125-140.](#)

## **JOURNAL ARTICLES**

[PUYOU DE POUVOURVILLE, G. \(2007\). Editorial : La réforme de la gouvernance hospitalière : mission impossible? \*La Presse Médicale\*, 36\(4\), pp. 636-637.](#)

[PUYOU DE POUVOURVILLE, G. \(2010\). Editorial: A French Approach to Cost-Effectiveness Analysis? \*European Journal of Health Economics\*, 11\(6\), pp. 521-523.](#)

[PUYOU DE POUVOURVILLE, G. \(2013\). Editorial: HAS to be NICE? \*European Journal of Health Economics\*, 14, pp. 363-366.](#)

[PUYOU DE POUVOURVILLE, G. \(2013\). Editorial: Paying Doctors for Performance. \*European Journal of Health Economics\*, 14\(1\), pp. 1-4.](#)

[CLERC, P., LEBRETON, J., MOUSQUES, J., HEBBRECHT, G. et PUYOU DE POUVOURVILLE, G. \(2008\). Etude polychrome : construction d'une typologie des pathologies chroniques en médecine générale, pour une analyse de la poly-prescription. \*Pratiques et Organisation des Soins\*, 39\(1\), pp. 43-51.](#)

[LUPORSI, E., MAHI, L., MORRE, C., WERNLI, J., PUYOU DE POUVOURVILLE, G. et BUGAT, R. \(2012\). Evaluation of Cost Savings with Ferric Carboxymaltose in Anemia Treatment Through Its Impact on Erythropoiesis-Stimulating Agents and Blood Transfusion: French Healthcare Payer Perspective. \*Journal of Medical Economics\*, 15\(2\), pp. 225-232.](#)

[CARO, J.J., NORD, E., MCGUIRE, A., MCGREGOR, D.H., PUYOU DE POUVOURVILLE, G. et ATELLA, V. \(2010\). IQWiG Methods – A Response to Two Critiques. \*Health Economics\*, 19\(10\), pp. 1137-1138.](#)

[PUYOU DE POUVOURVILLE, G. \(2010\). La crise d'identité des médecins face au nouveau management de l'hôpital. \*Journal de l'Ecole de Paris du Management\*, 6\(86\), pp. 22-29.](#)

[BORGET, I., REMY, H., CHEVALIER, J., RICARD, M., ALLYN, M. et DE POUVOURVILLE, G.](#)

[\(2008\). Length and Cost of Hospital Stay of Radioiodine Ablation in Thyroid Cancer Patients: Comparison between Preparation with Thyroid Hormone Withdrawal and Thyrogen. \*European Journal of Nuclear Medicine and Molecular Imaging\*, 35\(8\), pp. 1457-1463.](#)

[CHEVALIER, J., GIROUD, M. et PUYOU DE POUVOURVILLE, G. \(2013\). Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation. \*Cerebrovascular Diseases\*, 35\(4\), pp. 320-326.](#)

[RENARD, J.P., ROULAND, J.F., BRON, A., SELLEM, E., NORDMANN, J.P. et DE POUVOURVILLE, G. \(2013\). Nutritional, Lifestyle and Environmental Factors in Ocular Hypertension and Primary Open-Angle Glaucoma: An Exploratory Case-Control Study. \*Acta Ophthalmologica\*, 61\(6\), pp. 505-513.](#)

[CHOUAID, C., GERMAIN, N., PUYOU DE POUVOURVILLE, G., ABALLEA, S., KORCHAGINA, D. et BALDWIN, M. \(2019\). Patient preference for chronic obstructive pulmonary disease \(COPD\) treatment inhalers: a discrete choice experiment in France. \*Current Medical Research and Opinion\*, 35\(5\), pp. 785-792.](#)

[COHEN, S.Y., SOUIED, E.H., WEBER, A.P., DUPEYRON, G., PUYOU DE POUVOURVILLE, G. et LIEVRE, M. \(2011\). Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study. \*Graefe's Archive for Clinical and Experimental Ophthalmology\*, 249\(4\), pp. 521-527.](#)

[GARRISON, L.P., TOWSE, A., BRIGGS, A., PUYOU DE POUVOURVILLE, G., GRUEGER, J. et MOHR, P.E. \(2013\). Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. \*Value in Health\*, 16\(5\), pp. 703-719.](#)

[COHEN, A. et PUYOU DE POUVOURVILLE, G. \(2016\). Rapport coût/efficacité des traitements médicamenteux et interventionnels dans la fibrillation atriale. \*Archives of Cardiovascular Diseases Supplements\*, 8\(2\), pp. 141-143.](#)

[BELHASSEN, M., DE BLIC, J., LAFOREST, L., LAIGLE, V., CHANUT-VOGEL, C. et DE POUVOURVILLE, G. \(2016\). Recurrent Wheezing in Infants. \*Medicine\*, 95\(15\).](#)

[COTTE, F.E., MERCIER, F. et PUYOU DE POUVOURVILLE, G. \(2008\). Relationship Between Compliance and Persistence with Osteoporosis Medications and Fracture Risk in Primary Health Care in France: A Retrospective Case-control Analysis. \*Clinical Therapeutics\*, 30\(12\), pp. 2410-2422.](#)

[CARO, J.J., NORD, E., SIEBERT, U., MCGUIRE, A., MCGREGOR, M. et DE POUVOURVILLE, G. \(2010\). The Efficiency Frontier Approach to Economic Evaluation of Health-Care Interventions. \*Health Economics\*, 19\(10\), pp. 1117-1127.](#)

[SMOLDEREN, K.G., WANG, K., PUYOU DE POUVOURVILLE, G., BRÜGGENJÜRGEN, B., RÖTHER, J. et ZEYMER, U. \(2012\). Two-Year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for](#)

[Peripheral Arterial Disease. \*European Journal of Vascular and Endovascular Surgery\*, 43\(2\), pp. 198-207.](#)

[CLERC, P., LE BRETON, J., MOUSQUES, J., HEBBRECHT, G. et PUYOU DE POUVOURVILLE, G. \(2009\). Etude polychrome : une méthode d'expertise pour optimiser des vignettes de polyprescription en médecine générale. \*Pratiques et Organisation des Soins\*, 40\(3\), pp. 165-174.](#)

[NIXON, J., RICE, S., DRUMMOND, M., BOULENGER, S., ULMANN, P. et DE POUVOURVILLE, G. \(2009\). Guidelines for Completing the EURONHEED Transferability Information Checklists. \*European Journal of Health Economics\*, 10\(2\), pp. 157-165.](#)

[PUYOU DE POUVOURVILLE, G., BORGET, I. et SCHLUMBERGER, M. \(2007\). Health-related Quality of Life - An Economist's Perspective \(Viewpoint\). \*Nature Reviews Endocrinology\*, 3\(12\), pp. 2-3.](#)

[SCHLUMBERGER, M., RICARD, M., PUYOU DE POUVOURVILLE, G. et PACINI, F. \(2007\). How the Availability of Recombinant Human TSH Has Changed the Management of Patients Who Have Thyroid Cancer. \*Nature Reviews Endocrinology\*, 3\(9\), pp. 641-650.](#)

[PUYOU DE POUVOURVILLE, G. \(2016\). La Tarification à l'Activité est-elle Compatible avec les Valeurs des Professionnels de Santé ? \*Médecine de l'Homme\*, \(15\), pp. 11-25.](#)

[PUYOU DE POUVOURVILLE, G. \(2011\). L'assurance maladie en France: Beveridge et Bismarck enfin reconciliés? \*Réalités Industrielles \(série des "Annales des Mines"\)\*, pp. 19-24.](#)

[PUYOU DE POUVOURVILLE, G. \(2009\). Les hôpitaux français face au paiement prospectif au cas. La mise en œuvre de la tarification à l'activité. \*Revue Economique\*, 60\(2\), pp. 457-470.](#)

[PUYOU DE POUVOURVILLE, G. \(2016\). Quel prix payer pour un bénéfice en santé ? \*SEP et Neurosciences\*, \(5\), pp. 4-11.](#)

[PUYOU DE POUVOURVILLE, G. \(2007\). Qu'est-ce que la recherche en médecine générale ? \*La Revue du Practicien\*, 57\(11\), pp. 1181-1185.](#)

[TIBI-LEVY, Y. et PUYOU DE POUVOURVILLE, G. \(2009\). Qu'est-ce qu'une unité de soins "performante", du point de vue des malades relevant de soins palliatifs et de leurs proches ? \*Médecine palliative\*, 8\(2\), pp. 53-65.](#)

[TIBI-LEVY, Y., PUYOU DE POUVOURVILLE, G., WESTERLOPPE, J. et BAMBERGER, M. \(2008\). The Cost of Treating High Blood Pressure in General Practice in France. \*European Journal of Health Economics\*, 9\(3\), pp. 229-236.](#)

[BONASTRE, J., LE VAILLANT, M. et PUYOU DE POUVOURVILLE, G. \(2011\). The Impact of Research on Hospital Costs of Care: An Empirical Study. \*Health Economics\*, 20\(1\), pp. 73-84.](#)

[CHEVALIER, J. et PUYOU DE POUVOURVILLE, G. \(2011\). Valuing EQ-5D using Time Trade-Off in France. \*European Journal of Health Economics\*, 14\(1\), pp. 57-66.](#)

[DRUMMOND, M., PUYOU DE POUVOURVILLE, G., JONES, E., HAIG, J., SABA, G. et CAWSTON, H. \(2014\). A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France. \*Pharmacoeconomics\*, 32\(5\), pp. 509-520.](#)

[DEJARDIN, O., BOUVIER, A.M., FAIVRE, J., BOUTREUX, S., PUYOU DE POUVOURVILLE, G. et LAUNOY, G. \(2008\). Access to Care, Socioeconomic Deprivation and Colon Cancer Survival. \*Alimentary Pharmacology & Therapeutics\*, 27\(10\), pp. 940-949.](#)

[BONASTRE, J., CHEVALIER, J., VAN DER LAANC, C., DELIBESC, M. et PUYOU DE POUVOURVILLE, G. \(2014\). Access to Innovation: Is there a Difference in the Use of Expensive Anticancer Drugs Between French Hospitals? \*Health Policy\*, 116\(2&3\), pp. 162-169.](#)

[PUYOU DE POUVOURVILLE, G. \(2016\). Anticoagulants d'action directe: une revue de la littérature des études coût/efficacité en Europe. \*Archives of Cardiovascular Diseases Supplements\*, 8\(2\), pp. 180-191.](#)

[BORGET, I., VIELH, P., LEBOULLEUX, S., ALLYN, M., IACOBELLI, S. et DE POUVOURVILLE, G. \(2008\). Assessment of the Cost of Fine-needle Aspiration Cytology as a Diagnostic Tool in Patients with Thyroid Nodules. \*American Journal of Clinical Pathology\*, 129\(5\), pp. 763-771.](#)

[PERSONNE, V., CHEVALIER, J., BUFFEL DU VAURE, C., PARTOUCHE, H., GILBERG, S. et DE POUVOURVILLE, G. \(2016\). CAPECO: Cost Evaluation of Community Acquired Pneumonia Managed in Primary Care. \*Vaccine\*, 19\(34\), pp. 2275-2280.](#)

[COTTE, F.E. et PUYOU DE POUVOURVILLE, G. \(2011\). Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France. \*BMC Health Services Research\*, 151\(11\), pp. 1-10.](#)

[PUYOU DE POUVOURVILLE, G., SOLESSE, A. et BEILLAT, M. \(2008\). Cost-effectiveness Analysis of Aldosterone Blockade with Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction in the French Context: The EPHEBUS Study. \*Archives of Cardiovascular Diseases\*, 101\(9\), pp. 515-521.](#)

[GOODALL, G., LAMOTTE, M., RAMOS, M., MAUNOURY, F., PEJCHALOVA, B. et DE POUVOURVILLE, G. \(2019\). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. \*Journal of Medical Economics\*, 22\(4\), pp. 289-296.](#)

[BONASTRE, J., CHEVALIER, J., ELIAS, D., CLASSE, J.M., FERRON, G. et DE POUVOURVILLE, G. \(2008\). Cost-effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer. \*Value in Health\*, 11\(3\), pp. 347-353.](#)

[PUYOU DE POUVOURVILLE, G. \(2016\). Coût de la Prise en Charge des Accidents Vasculaires Cérébraux en France. \*Archives of Cardiovascular Diseases Supplements\*, 8\(2\), pp. 161-168.](#)

[COTTE, F.E., FAUTREL, B. et PUYOU DE POUVOURVILLE, G. \(2009\). A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis. \*Medical\*](#)

[Decision Making, 29\(1\), pp. 125-139.](#)

[PUYOU DE POUVOURVILLE, G. \(2009\). Exploitation seconde de la base de l'Etude nationale de coûts \(ENC\). \*Dossiers Solidarité et santé\*, \(9\), pp. 2-6.](#)

[PUYOU DE POUVOURVILLE, G. \(2016\). Comment Améliorer le Suivi des AVK et pour quel Coût? \*Archives of Cardiovascular Diseases Supplements\*, 8\(2\), pp. 169-173.](#)

[DE POUVOURVILLE, G. \(2025\). L'évolution de la place de l'évaluation économique en santé en France. \*médecine/sciences\*, 41, pp. 119-132.](#)

[DE POUVOURVILLE, G., BORGET, I. et SCHLUMBERGER, M. \(2007\). Calcitonin determination in patients with nodular thyroid disease. \*The Journal of Clinical Endocrinology & Metabolism\*, 92\(2\), pp. 425-427.](#)

[DE POUVOURVILLE, G., BONASTRE, J., DE BAÈRE, T., ELIAS, D. et SERGE, E. \(2007\). Cost of radiofrequency ablation in the treatment of hepatic malignancies. \*Gastroentérologie Clinique et Biologique\*, 31, pp. 828-835.](#)

[DE POUVOURVILLE, G. et SPIELER, J.F. \(2007\). Evaluation du coût de la prise en charge ambulatoire des patients après AVC: résultats d'une enquête postale auprès des patients du registre des AVC de Dijon. \*La Presse Médicale\*, 36\(3\), pp. 399-403.](#)

[DE POUVOURVILLE, G., HALLAIS, C., CZERNICHOW, P., LE VAILLANT, M. et FROMENT, L. \(2007\). Gravité des patients et surcoûts dans les hôpitaux de référence. \*Journal d'Economie Médicale\*, 25\(3\), pp. 177-187.](#)

[DE POUVOURVILLE, G., BORGET, I. et SCHLUMBERGER, M. \(2007\). Health-related quality of life- an economist's perspective. \*Nature Clinical Practice Endocrinology & Metabolism\*, 3, pp. 786-787.](#)

[DE POUVOURVILLE, G. et PRIOLLET, P. \(2007\). Impact du choix d'une thérapie anti-agrégante dans l'artériopathie des membres inférieurs: étude coût-efficacité et impact économique. \*Journal des Maladies Vasculaires\*, 32\(1\), pp. 8-14.](#)

[BONASTRE, J., CHEVALIER, J., GÉRARD, J.P., LEFKOPOULOS, D. et DE POUVOURVILLE, G. \(2007\). Implications of learning effects for hospital costs of new technologies: the case of intensity modulated radiation therapy. \*International Journal of Technology Assessment in Health Care\*, 23\(2\), pp. 248-254.](#)

[DE POUVOURVILLE, G. \(2007\). La recherche en médecine générale en France: état es lieux. \*La Revue du Practicien\*, 57\(11\), pp. 1200-1202.](#)

[DE POUVOURVILLE, G. \(2007\). Réformer la gouvernance de l'hôpital: mission impossible? \*La Presse Médicale\*, 36\(4\), pp. 636-637.](#)

[DE POUVOURVILLE, G., BORGET, I., CORONE, C., NOCAUDIE, M. et ALLYN, M. \(2007\). Sick](#)

[leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. \*European Journal of Endocrinology\*, 156\(5\), pp. 531-538.](#)

[DE POUVOURVILLE, G., TIBI-LÉVY, Y., BAMBERGER, M. et WESTTERLOPPE, J. \(2007\). The cost of treating high blood pressure in France. \*European Journal of Health Economics\*.](#)

[DE POUVOURVILLE, G., BLIN, P. et KARAM, P. \(2020\). The Contribution of Real-World Evidence to Cost-Effectiveness Analysis: Case Study of Dabigatran Etxilate in France. \*European Journal of Health Economics\*, 21, pp. 235-249.](#)

[ANDRADE, L.F., LUDWIG, K., RAMOS GONI, J.M., OPPE, M. et DE POUVOURVILLE, G. \(2020\). A French Value Set for the EQ-5D-5L. \*Pharmacoeconomics\*, 38\(1\), pp. 1-13.](#)

[DE POUVOURVILLE, G. et KARAM, P. \(2019\). Le coût hospitalier des événements cérébro-vasculaires associés à une fibrillation atriale en France. \*Journal de Gestion et d'Économie de la Santé\*, 37\(5\), pp. 399-409.](#)

[TÉHARD, B., DETOURNAY, B., BORGET, I., ROZE, S. et PUYOU DE POUVOURVILLE, G. \(2020\). Value of a QALY for France: A New Approach to Propose Acceptable Reference Values. \*Value in Health\*, 23\(8\), pp. 985-993.](#)

[DALON, F., MAJED, L., BELHASSEN, M., JACOUD, F., BÉRARD, M., LÉVY-BACHELOT, L. ... BALDAUF, J.J. \(2021\). Human papillomavirus \(HPV\) vaccine coverage rates \(VCRs\) in France: A French claims data study. \*Vaccine\*, 39\(36\), pp. 5129-5137.](#)

[SMITH, A.B., HANBURY, A., BEITIA ORTIZ DE ZARATE, I., HAMMES, F., PUYOU DE POUVOURVILLE, G. et BUESCH, K. \(2021\). Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase \(AADC\) Deficiency: A Vignette Study in France. \*Patient Related Outcome Measures\*, 12, pp. 237-246.](#)

[ROUSSEL, R., RIVELINE, J.P., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. ... GUERCI, B. \(2021\). Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. \*Diabetes Care\*, 44\(6\), pp. 1368-1376.](#)

[QUINN, C., GARRISON, L.P., POWNELL, A.K., ATKINS, M.B., PUYOU DE POUVOURVILLE, G., HARRINGTON, K. ... WU, E. \(2020\). Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. \*Journal for ImmunoTherapy of Cancer\*, 8\(2\), pp. e000648.](#)

[RICHARD, M., PAUL, C., PUYOU DE POUVOURVILLE, G., JULLIEN, D., MAHE, E., BACHELEZ, H. ... EZZEDINE, K. \(2021\). Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. \*Journal of the European Academy of Dermatology and Venereology\*, 35\(4\), pp. 912-918.](#)

[PUYOU DE POUVOURVILLE, G. \(2021\). Logique médicale, économique, industrielle et politique dans la définition du « prix » du médicament. \*Revue d'Économie Financière\*, 2021/3\(143\), pp.](#)

[213-229.](#)

[SMITH, A., HANBURY, A., WHITTY, J., BEITIA ORTIZ DE ZARATE, I., PUYOU DE POUVOURVILLE, G., HAMMES, F. et BUESCH, K. \(2022\). A Discrete Choice Experiment to Derive Health Utilities for Aromatic L-Amino Acid Decarboxylase \(AADC\) Deficiency in France. \*Patient Related Outcome Measures\*, \(13\), pp. 21-30.](#)

[THURIN, N., ROUYER, M., JOVÉ, J., GROSS-GOUPIL, M., HAASER, T., REBILLARD, X. ... BLIN, P. \(2022\). Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database. \*Expert Review of Clinical Pharmacology\*, 15\(9\), pp. 1139-1145.](#)

[WITHALL, A., JOMMI, C., PUYOU DE POUVOURVILLE, G., TAYLOR, D., ANNEMANS, L., SCHOONAERT, L. ... PATRIS, J. \(2022\). Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. \*International Journal of Technology Assessment in Health Care\*, 38\(1\), pp. e23, 1-8.](#)

[GUERCI, B., ROUSSEL, R., LEVRAT-GUILLEN, F., DETOURNAY, B., VICAUT, E., PUYOU DE POUVOURVILLE, G. ... RIVELINE, J.P. \(2023\). Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France. \*Diabetes Technology & Therapeutics\*, 25\(1\), pp. 1-30.](#)

[GAUTIER, L., AZZI, J., SABA, G., BONNELYE, G. et PUYOU DE POUVOURVILLE, G. \(2023\). Population norms in France with EQ-5D-5L: health states, value indexes, and VAS. \*European Journal of Health Economics\*, 24\(9\), pp. 1517-1530.](#)

[PUYOU DE POUVOURVILLE, G., ARMOIRY, X., LAVOREL, A., BILBAULT, P., MAUGENDRE, P., BENSIMON, L. ... VIPREY, M. \(2023\). Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials? \*Therapies\*, 78\(1\), pp. 81-94.](#)

[PUYOU DE POUVOURVILLE, G., CUNNINGHAM, D., FRICKE, F.U., LINDGREN, P. et MANTOVANI, L. \(2023\). Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. \*Value in Health\*, 26\(4\), pp. 11-19.](#)

[WANG, W., KOTHARI, S., KHOURY, H., NICCOLAI, L., GARLAND, S.M., SUNDSTRÖM, K. ... FRANCO, E.L. \(2023\). A review of data systems for assessing the impact of HPV vaccination in selected high-income countries. \*Expert Review of Vaccines\*, 22\(1\), pp. 161-179.](#)

[PUYOU DE POUVOURVILLE, G., ULMANN, P., NIXON, J., BOULENGER, S., GLANVILLE, J. et DRUMMOND, M. \(2012\). The Diffusion of Health Economics Knowledge in Europe. \*Pharmacoeconomics\*, 23\(2\), pp. 113-120.](#)

[GILARD, M., ELTCHANINOFF, H., IUNG, B., LEFÈVRE, T., SPAULDING, C., DUMONTEIL, N. ... SHORE, J. \(2022\). Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France. \*Value in Health\*, 25\(4\), pp. 605-613.](#)

[RIVELINE, J.P., ROUSSEL, R., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. ... GUERCI, B. \(2022\). Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. \*Diabetes Technology & Therapeutics\*, 24\(9\), pp. 611-618.](#)

[HENSHALL, C.H., DANKÓ, D., BARHAM, L., ESPÍN, J., FELIX, J., HARNEY, M. ... WILKING, N. \(2023\). Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe. \*Applied Health Economics and Policy\*, 21\(4\), pp. 537-546.](#)

[SOLÀ-MORALES, O., SIGURÐARDÓTTIR, K., AKEHURST, R., MURPHY, L.A., MESTRE-FERRANDIZ, J., CUNNINGHAM, D. et PUYOU DE POUVOURVILLE, G. \(2023\). Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. \*Value in Health\*, 26\(4\), pp. 32-42.](#)

[GUERCI, B., LEVRAT-GUILLEN, F., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. et RIVELINE, J.P. \(2023\). Reduced Acute Diabetes Events After FreeStyle Libre System Initiation in People 65 Years or Older with Type 2 Diabetes on Intensive Insulin Therapy in France. \*Diabetes Technology & Therapeutics\*, 25\(6\), pp. 384-394.](#)

[DRUMMOND, M., CIANI, O., FORNARO, G., JOMMI, C., DIETRICH, E.S., ESPIN, J. ... PUYOU DE POUVOURVILLE, G. \(2023\). How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? \*BMC Health Services Research\*, 23\(484\).](#)

[AKEHURST, R., MURPHY, L.A., SOLÀ-MORALES, O., CUNNINGHAM, D., MESTRE-FERRANDIZ, J. et PUYOU DE POUVOURVILLE, G. \(2023\). Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward. \*Value in Health\*, 26\(4\), pp. 11-19.](#)

[MURPHY, L.A., AKEHURST, R., SOLÀ-MORALES, O., CUNNINGHAM, D., MESTRE-FERRANDIZ, J., FRANKLIN, M. et PUYOU DE POUVOURVILLE, G. \(2023\). Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers. \*Value in Health\*, 26\(4\), pp. 20-31.](#)

[ALLANORE, Y., CONSTANS, J., GODARD, D., PUYOU DE POUVOURVILLE, G., BOUEE, S., JEANBAT, V. ... HACHULLA, E. \(2022\). Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. \*Journal of Scleroderma and Related Disorders\*, 7\(1\), pp. 49-56.](#)

[MISERY, L., SHOURICK, J., SÉNÉSCHAL, J., PAUL, C., PUYOU DE POUVOURVILLE, G., JULLIEN, D. ... RICHARD, M.A. \(2021\). Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients. \*American Journal of Clinical Dermatology\*, 22\(2\), pp. 285-287.](#)

[JULLIEN, D., PAUL, C., SHOURICK, J., SÉNÉSCHAL, J., PUYOU DE POUVOURVILLE, G., MISERY, L. ... RICHARD, M.A. \(2021\). Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients. \*Journal of the European Academy of Dermatology and Venereology\*, 35\(4\), pp. e301-e303.](#)

[PUYOU DE POUVOURVILLE, G., ROSSIGNOL, P., BOUSSAHOUA, M., CHEVALIER, J., GABB, P.D., POULNAIS, R. ... GARCIA SANCHEZ, J.J. \(2023\). Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective. \*Advances in Therapy\*, 40, pp. 3751-3769.](#)

[SALORT-CAMPANA, E., LAFORET, P., PUYOU DE POUVOURVILLE, G., CROCHARD, A., CHOLLET, G., NEVORET, C. ... TARD, C. \(2024\). Epidemiology of myasthenia gravis in France: A retrospective claims database study \(STAMINA\). \*Revue Neurologique\*, 180\(3\), pp. 202-210.](#)

[LOUBET, P., FERNANDES, J., PUYOU DE POUVOURVILLE, G., SOSNOWIEZ, K., ELONG, A., GUILMET, C. ... CHAKRA, C.N.A. \(2024\). Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study. \*Journal of Clinical Virology\*, 171, pp. 105635.](#)

[SZAFRANSKI, K., PUYOU DE POUVOURVILLE, G., GREENBERG, D., HARRIS, S., JENDLE, J., SHAW, J.E. ... LEVRAT-GUILLEN, F. \(2024\). The Determination of Diabetes Utilities, Costs, and Effects Model, A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation. \*Value in Health\*, 27\(4\), pp. 500-507.](#)

[VIGUIER, M., BENTAYEB, M., AZZI, J., PUYOU DE POUVOURVILLE, G., GLOEDE, T., LANGELLIER, B. ... BACHELEZ, H. \(2024\). Generalized pustular psoriasis: A nationwide population?based study using the National Health Data System in France. \*Journal of the European Academy of Dermatology and Venereology\*, 38\(6\), pp. 1131-1139.](#)

[PUYOU DE POUVOURVILLE, G. \(2024\). Les cellules CAR-T : prix, efficience et soutenabilité en France. \*Bulletin de l'Académie Nationale de Médecine\*, 208\(5\), pp. 590-601.](#)

[DERVAUX, B., BASEILHAC, E., FAGON, J.Y., AMEYE, V., ANGOT, P., AUDRY, A. ... SUN, A. \(2013\). Medico-economic Evaluation of Health Products in the Context of the Social Security Financing Act for 2012. \*Therapies\*, 68\(4\), pp. 259-263.](#)

[ANDRADE, L.F., SABA, G., RICARD, J.D., MESSIKA, J., GAILLAT, J., BONNIN, P. ... PUYOU DE POUVOURVILLE, G. \(2018\). Health related quality of life in patients with community-acquired pneumococcal pneumonia in France. \*Health and Quality of Life Outcomes\*, 16\(1\).](#)

[BELHASSEN, M., PUYOU DE POUVOURVILLE, G., LAFOREST, L., BROUARD, J., DE BLIC, J., FAUROUX, B. ... VAN GANSE, E. \(2015\). Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study. \*BMC Pulmonary Medicine\*, 15\(Art. 51\).](#)

[PUYOU DE POUVOURVILLE, G., BREAU-BRUNEL, M., LONCLE-PROVOT, V., BECK, E., GAUGAIN, L., NACHBAUR, G. et PRIBIL, C. \(2024\). Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France. \*PharmacoEconomics - Open\*, 8\(4\), pp. 539-557.](#)

[PUYOU DE POUVOURVILLE, G., GUYOT, E., FARGE, G., BELHASSEN, M., BÉRARD, M., JACOUD, F. ... BALDAUF, J.J. \(2024\). Human Papillomavirus \(HPV\) vaccination coverage among](#)

[French adolescents: A claims data study. \*Vaccine\*, 17\(42\), pp. 126039.](#)

[MINVIELLE, E., LELEU, H., MASSETI, M., FERREIRA, A., PUYOU DE POUVOURVILLE, G., PALMA, M.D. et SCOTTÉ, F. \(2025\). A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial. \*European Journal of Health Economics\*, 26\(2\), pp. 267-273.](#)

[RIVELINE, J.P., LEVRAT-GUILLEN, F., DETOURNAY, B., VICAUT, E., PUYOU DE POUVOURVILLE, G., EMERY, C. et GUERCI, B. \(2024\). Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre® System Initiation in Some People With Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy Without Insulin in France. \*Diabetes Technology & Therapeutics\*, 26\(12\), pp. 932-938.](#)

[LARGERON, N., D'AGOSTINO, P., CHAPMAN, R., DANKO, D., ESKOLA, J., GODFROID, P. ... BECK, E. \(2024\). Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union's Regulation on Health Technology Assessment for Vaccines. \*Value in Health\*, 27\(10\), pp. 1318-1327.](#)

[CHOQUET, S., MARCHAL, C., DEYGAS, F., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G. et LEVY, V. \(2024\). A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database \(OSIRIS\). \*Annals of Hematology\*, 103\(8\), pp. 2969-2981.](#)

[TARD, C., LAFORET, P., DE POUVOURVILLE, G., CROCHARD, A., CHOLLET, G., NEVORET, C. ... SALORT-CAMPANA, E. \(2024\). Treatment of myasthenia gravis in france: A retrospective claims database study \(STAMINA\). \*Journal of Neurology\*, 271\(11\), pp. 7239-7249.](#)

[CHOUAID, C., MARCHAL, C., APERT, M., BENSIMON, L., GUIMARD, V., NÉE, M. ... BLAY, J.Y. \(2025\). Epidemiology of metastatic lung cancer in France between 2013 and 2021: Observational study using the French claims database. \*Bulletin du Cancer\*, 112\(2\), pp. 166-177.](#)

[AJJAN, R.A., BATTELINO, T., SEUFERT, J., BLIN, P., DE POUVOURVILLE, G., VICAUT, E. ... JOUBERT, M. \(2025\). Do continuous glucose monitoring \(CGM\) metrics predict macrovascular and microvascular complications in diabetes? The FACULTY protocol of a retrospective real-world cohort study. \*BMJ Open\*, 15\(1\), pp. e085961.](#)

[MURPHY, L.A., AKEHURST, R., CUNNINGHAM, D., DE POUVOURVILLE, G. et SOLÀ-MORALES, O. \(2025\). Real-world evidence to support health technology assessment and payer decision making: is it now or never? \*International Journal of Technology Assessment in Health Care\*, 41\(1\), pp. e20, 1-7.](#)

[BAILEY, M.D., FARGE, G., MOHANTY, S., BREAU-BRUNEL, M., ROY, G., DE POUVOURVILLE, G. ... JOHNSON, K.D. \(2025\). Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study. \*Human Vaccines & Immunotherapeutics\*, 21\(1\), pp. 2515760.](#)

[CHOUAID, C., MARCHAL, C., APERT, M., BENSIMON, L., GUIMARD, V., NÉE, M. ... BLAY, J.Y. \(2025\). Change in healthcare resource use and associated costs of patients with metastatic lung](#)

[cancer between 2013 and 2021: an observational study from the French national health data system. \*European Journal of Health Economics\*, In press.](#)

[HANON, O., COHEN, A., JOURDAIN, P., LERAY, E., DE POUVOURVILLE, G., GOGUILLOT, M. ... LOGEART, D. \(2025\). Real-world persistence with sacubitril/valsartan in patients with heart failure in France: A claims database study. \*Archives of Cardiovascular Diseases\*, In press.](#)

[CORCIA, P., STENSON, K., DOUTRIAUX, A., HADJRABIA, H., BOER, F., ISSA, S. ... COURATIER, P. \(2025\). Epidemiology, disease evolution and economic burden of amyotrophic lateral sclerosis in France using the French national health data system. \*Brain Communications\*, 7\(4\), pp. fcaf292.](#)

## **INTERVIEWS: RADIO - TV - PRESS**

[PUYOU DE POUVOURVILLE, G. 2016. \*La territorialisation aux mains des CPTS et des GHT\*. Décembre.](#)

## **BOOK EDITOR**

[KIMBERLY, J., PUYOU DE POUVOURVILLE, G. et D'AUNNO, T. \[Eds\] \(2008\). \*The Globalization of Managerial Innovation in Health Care\*. Cambridge University Press, 379 pages.](#)

[BRAS, P.L., PUYOU DE POUVOURVILLE, G. et TABUTEAU, D. \[Eds\] \(2009\). \*Traité d'économie et de gestion de la santé\*. Presses de Sciences Po, 564 pages.](#)

## **CONFERENCE PROCEEDINGS**

[PUYOU DE POUVOURVILLE, G. \(2016\). \*Le territoire dans la régulation du système de santé\*. Dans: \*Management hospitalier et territoire: les nouveaux défis\*. Presses des Mines.](#)

[FEARON, W., BORNSCHEIN, B., ARVANDI, M., GOTHE, R., RIOUFOL, G., DE BRUYNE, B. ... SIEBERT, U. \(2011\). Cost-effectiveness of fractional flow reserve measurement in multivessel coronary artery disease in Belgium and in France. Dans: \*ISPOR Europe. Value in Health\*, pp. 251.](#)

## **CONFERENCE PROCEEDINGS EDITOR**

[PUYOU DE POUVOURVILLE, G. \(2009\). 26th Scientific Plenary Meeting of the EuroQol Group. EuroQol Group, Pays-Bas.](#)

## PRESENTATIONS AT AN ACADEMIC OR PROFESSIONAL CONFERENCE

[CHOQUET, S., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G., MARCHAL, C., BELHASSEN, M. ... LEVY, V. \(2022\). Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database \(OSIRIS\). Dans: American Society of Hematology Conference.](#)

[COAQUIRA CASTRO, J., PUYOU DE POUVOURVILLE, G., GREENBERG, D., HARRIS, S., JENDLE, J., SHAW, J. ... SZAFRANSKI, K. \(2022\). P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes. Dans: ISPOR Europe 2022. Vienna & Virtual.](#)

[MOLNAR, A., STÖRZEL, M., MUCHADEYI, M., BAIRD, R., IMAZ-IGLESIA, I., NAGY, B. ... SCHLANDER, M. \(2022\). MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop. Dans: ISPOR Europe 2022. Vienna & Virtual.](#)

[SIGURÐARDÓTTIR, K., SOLA-MORALES, O., MURPHY, L., CORRY, S., MESTRE-FERRANDIZ, J., CUNNINGHAM, D. ... PUYOU DE POUVOURVILLE, G. \(2022\). POSB405 Data Governance for Rwd/E Management: Optimising Its Use in HTA and Decision-Making. Dans: Virtual ISPOR Europe 2021 Meeting.](#)

## OTHER

[WHITTAL, A., JOMMI, C., PUYOU DE POUVOURVILLE, G., TAYLOR, D., ANNEMANS, L., SCHOONAERT, L. ... PATRIS, J. \(2022\). Facilitating \[corrected\] More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. International Journal of Technology Assessment in Health Care.](#)

## RESEARCH ACTIVITIES

### Function in an academic association

- 2000 - 2005: President of the Collège des Economistes de la Santé, member of the Conseil d'Administration, hence scientific supervisor of the organization of two international symposia; promoter of the basis of the documentary « Connaissance et Décision en Economie de la Santé », creator of the European network (16 countries) of documentary databases in Health Economics "EURONHEED"; co-supervisor of the writing of « Recommandations pour l'évaluation économique des stratégies de santé ». (France)
- 2001 - 2006: Member of the Comité Directeur of IFR "Epidémiologie, Santé Publique, Sciences Sociales"
- 2000 - 2006: Coordinator of the Comité d'Interface INSERM/Médecine Générale

- 2000 - 2006: Member of the Comité Scientifique Sciences Humaines et Sociales, Institut National du Cancer.
- 2002 - 2005: Designated member of the board of directors of INSERM
- 1995 - 2000: Elected member of the Comité National, section 37 « Economie et Société »
- 1990 - 1995: Designated member of the Scientific Council of INSERM
- 1995 - 1999: Member of the Scientific Council of Ecole Nationale de la Santé Publique
- 1998 - 1998: Member of the scientific evaluation mission of Agence Nationale de Recherche sur le SIDA, Ministère de la Recherche et de la Technologie.
- 1998 - 2000: Member of the Scientific Council of Institut Paoli Calmettes
- 1995 - 1998: Member of the Scientific Council of Institut d'Etude des Politiques de Santé, Paris V.
- 1996 - 1998: Scientific supervisor of the France-Québec scientific cooperation program "Economie de la Santé".
- 1997 - 2000: Member of the Scientific Council of Institut Universitaire de Santé Publique of Ile de France
- 1992 - 1994: Scientific Committee President of the invitation to tender "Evaluation Economique des Stratégies Préventives et Thérapeutiques", Ministère de la Recherche

#### **Member of an academic association**

- 1950 - Now: Member of the International Health Economics Association (IHEA)

#### **Role as an expert or appraiser in a research organization**

- 1950 - Now: Member of the Scientific Council of Mission Innovation, Recherche et Expérimentation (MIRE), DREES, Ministère de la Santé ( France)
- 1995 - Now: Member of the Scientific Council of l'Institut de Recherche et de Documentation en Economie de la Santé (IRDES), Caisse Nationale d'Assurance Maladie ( France)
- 1950 - Now: Member of the Steering Committee on research operations of Haute Autorité de Santé ( France)

#### **Reviewer for a journal**

- Reviewer for European Journal of Health Economics
- Gérer et Comprendre
- Health Economics
- International Journal of Technology Assessment in Health Care
- Pharmacoeconomics
- Politiques et Management Public
- Revue Française de Gestion
- Social Science and Medicine

### **Organization of a conference or a seminar**

1989 - 1998: Organization and co-organization of 8 symposia and research seminars, 3 of them as a member of the scientific committee of "mini-symposia" INSERM

### **Editorial Board Membership**

2016 - 2018: Editorial board membership - Gérer et Comprendre

## **PROFESSIONAL ACTIVITIES**

### **Member of a professional association, of an expert group or of a board of directors**

1950 - Now: Member of the Commission des Comptes de la Santé

1950 - Now: Scientific expert for the Mission Tarification à l'Activité, Ministère de la Santé-Participation in the working group on the topic : Financement des Missions d'Intérêt Général et d'Aide à la Contractualisation ( France)

1950 - Now: Invited Expert, Ministère de la Santé et du Bien-être, Province d'Alberta, Canada. ( Canada)

1950 - Now: Member of the Global Health Outcome Board, Groupe Glaxo-Smith-Kline

1992 - Now: Member of the Groupe de Prospective Santé 2010, Commissariat Général au Plan ; writer of the health system regulation regionalization scenario (Rapport Santé 2010, under the supervision of Raymond Soubie) ; to this end writer of a synthesis presenting a creation project of Health Regional Agencies.

2004 - 2004: Member of the Comité d'Experts, Tarification à l'Activité, Ministère de la Santé

### **Consulting**

1950 - Now: For the Ministre de la Santé and the Ministre Délégué à la Recherche, about the development of general medicine research in France. ( France)

1950 - Now: Consultant, Centre Hospitalier Régional Universitaire de Lille, evaluation of the Missions d'Intérêt Général et d'Aide à la Contractualisation, as part of the Tarification à l'Activité. ( France)

1950 - Now: Consultant for the laboratories: MSD, Sanofi-Aventis, Astra-Zeneca, Pfizer, Servier, Procter& Gamble, BMS, Bayer SA.

1982 - 1996: Consultant for the Direction des Hôpitaux, Ministère de la Santé; conception of medical information systems for hospitals, in charge of the development of a budgetization method based on the medical activity of the establishments ; participation in the writing of Etude Nationale des Coûts.

1983 - 1984: Consultant for Direction Générale de la Santé, Ministère de la Santé; expert for the Commission Nationale d'Anesthésiologie about specialty demography regulation.

1974 - 1974: Consultant for OECD, on the project "Politiques pour l'innovation dans le secteur des services".

2004 - 2004: Consultant for Centre Hospitalier de Lagny-Marne-la-Vallée: implementation of intern contractualization

2003 - 2003: Expert for the Royal Commission for the reform of the Canadian Health System (Romanow Commission)

2001 - 2003:

Vice-President of the Comité d'Orientation, Observatoire des Prescriptions et de la Consommation des Médicaments, Ministère de la Solidarité Nationale, de l'Emploi et de la Santé.